BIOMAT Database Logo BIOMAT Database Logo

Sequence-dependent antitumor effect of VP-16 and 1-beta-D-arabinofuranosylcytosine in L1210 ascites tumor. 1988

T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Department of Pediatrics, Mie University, School of Medicine, Japan.

The sequence-dependence of the antitumor effect of etoposide (VP-16) and 1-beta-D-arabinofuranosylcytosine (ara-C) was investigated against the L1210 ascites tumor in BDF1 mice. Treatment with VP16 (7.5 or 15 mg/kg) and ara-C (25 or 500 mg/kg) was administered intraperitoneally on days 1, 4 and 7 after tumor inoculation. Six hour pretreatment with 15 mg/kg VP16 followed by 500 mg/kg ara-C yielded a 100% cure rate, but only a 20% cure rate was obtained with the reverse sequence. Simultaneous administration of 15 mg/kg of VP-16 and 500 mg/kg ara-C interacted synergistically, producing a 70% cure rate. In contrast with the results obtained with VP-16 and 500 mg/kg ara-C, simultaneous administration of 25 mg/kg ara-C neither antagonized nor potentiated the antitumor effect of VP-16. Twenty-five mg/kg ara-C was too low to produce any antitumor effect with VP-16 in simultaneous administration. At every dose investigated, pretreatment with VP-16 followed by ara-C was the most effective antitumor schedule in L1210 leukemia. This sequence of drug administration did not cause greater toxicity as measured by weight loss or toxic death.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
April 1970, Cancer research,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Cell kinetic studies of the cytostatic and cytocidal effect of 1-beta-D-arabinofuranosylcytosine on the L1210 ascites tumor.
March 1984, Cancer research,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210.
April 1968, Cancer research,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells.
February 1981, Cancer research,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Biochemical and antitumor effects of the combination of thymidine and 1-beta-D-arabinofuranosylcytosine against leukemia L1210.
February 1981, Cancer research,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Modulation of the effect of 1-beta-D-arabinofuranosylcytosine by 6-mercaptopurine in L1210 cells.
September 1994, Japanese journal of cancer research : Gann,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.
September 1980, Cancer research,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.
July 1989, Japanese journal of cancer research : Gann,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Dose-dependent cytokinetic changes following 1-beta-D-arabinofuranosylcytosine and hydroxyurea in L1210 and S-180 in vivo.
September 1978, Cell and tissue kinetics,
T Ohkubo, and M Higashigawa, and H Kawasaki, and H Kamiya, and M Sakurai, and Y Kagawa, and E Kakito, and K Sumida, and K Ooi
Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
March 1976, Cancer research,
Copied contents to your clipboard!